rs797045005
Variant summary
Our verdict is Pathogenic. Variant got 17 ACMG points: 17P and 0B. PM1PM2PM5PP2PP3_ModeratePP5_Very_Strong
The NM_006009.4(TUBA1A):c.1226T>C(p.Val409Ala) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V409I) has been classified as Likely pathogenic.
Frequency
Consequence
NM_006009.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 17 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
TUBA1A | NM_006009.4 | c.1226T>C | p.Val409Ala | missense_variant | 4/4 | ENST00000301071.12 | |
TUBA1A | NM_001270399.2 | c.1226T>C | p.Val409Ala | missense_variant | 4/4 | ||
TUBA1A | NM_001270400.2 | c.1121T>C | p.Val374Ala | missense_variant | 4/4 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
TUBA1A | ENST00000301071.12 | c.1226T>C | p.Val409Ala | missense_variant | 4/4 | 1 | NM_006009.4 | P1 | |
TUBA1B-AS1 | ENST00000656133.1 | n.474-3143A>G | intron_variant, non_coding_transcript_variant |
Frequencies
GnomAD3 genomes ? Cov.: 32
GnomAD4 exome Cov.: 30
GnomAD4 genome ? Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Invitae | Jan 29, 2021 | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Val409 amino acid residue in TUBA1A. Other variant(s) that disrupt this residue have been observed in individuals with TUBA1A-related conditions (PMID: 24860126), which suggests that this may be a clinically significant amino acid residue. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has been observed in individual(s) with cortical malformations (PMID: 24860126, 32581362, Invitae). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 208490). This variant is not present in population databases (ExAC no frequency). This sequence change replaces valine with alanine at codon 409 of the TUBA1A protein (p.Val409Ala). The valine residue is highly conserved and there is a small physicochemical difference between valine and alanine. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 29, 2018 | A variant that is likely pathogenic has been identified in the TUBA1A gene. The V409A variant has been reported previously as a de novo variant in a pregnancy with severe lissencephaly and cerebellar hypoplasia; however, functional characterization of the variant was not completed (Bahi-Buisson et al., 2014). The V409A variant is not observed in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). The V409A variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. However, this substitution occurs at a position that is conserved across species, and in silico analysis predicts this variant is probably damaging to the protein structure/function. Furthermore, a missense variant in the same residue (V409I) has been reported in association with a TUBA1A-related disorder (Bahi-Buisson et al., 2014). Therefore, this variant is likely pathogenic; however, the possibility that it is benign cannot be excluded. - |
Lissencephaly due to TUBA1A mutation Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 18, 2022 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Mendelics | Jul 01, 2014 | - - |
Cryptorchidism;C0175754:Corpus callosum, agenesis of;C0266463:Lissencephaly Pathogenic:1
Pathogenic, no assertion criteria provided | research | NIHR Bioresource Rare Diseases, University of Cambridge | - | - - |
Tubulinopathy Pathogenic:1
Pathogenic, criteria provided, single submitter | literature only | Institute of Human Genetics, FAU Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg | Jul 01, 2018 | A variant that is classified as pathogenic has been identified in the TUBA1A gene in a 32 gestational week old fetal individual of male sex. The c.1226T>C, p.(Val409Ala) variant has been reported as a variant of de novo origin. This variant and associated phenotype was previously reported by Bahi-Buisson et al. Brain, 2014 PMID: 24860126. HPO-standardized clinical features were: Agenesis of the corpus callosum (HP:0001274); Agyria-pachygyria (HP:0031883, HP:0001302); Cerebellar vermis hypoplasia (HP:0001320); Hypoplasia of the brainstem (HP:0002365); Cerebellar hypoplasia (HP:0001321); no Congenital microcephaly (-HP:0011451) - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at